top of page
P29 White Logo.png

Project-29 is advancing cancer screening, diagnostics and therapeutic monitoring – in humans and companion animals.

Cancer is

Transformative

P29 White Logo.png

Aims to define 

​

What the cancer

IS

DOING

Cellular changes in Metabolism, 

Proliferation, and Inflammation  define key activities in cancer.

Thymidine Kinase Type 1

C-Reactive Protein

Isotopic Copper 

Ratio

Thymidine Kinase Type 1

P29 Diagram_white.png

Metabolism

The deregulation of cellular energetics is a biochemical fingerprint of cancer.

​

Cancer changes how energy is produced, typically from OXPHOS to aerobic glycolysis (Warburg effect). However, cancer is a heterogenous disease and each cancer may behave differently or even switch as demands dictate.

​

Copper is essential for energy production and changing states may alter the stable, non-radioactive, isotopes 65Cu 63Cu. The ratio of these two isotopes δ(65)Cu provide insight into metabolic processes.

Warburg Effect_with logo.jpg

Proliferation

Unchecked proliferation is a

hallmark of cancer.

​

Cell division is dysregulated. A proven marker of dysregulated proliferation is thymidine kinase, type 1 (TK1) that makes the nucleotide thymine via the “salvage pathway”.

​

TK1 is upregulated in proportion to rate of growth, overall tumor burden, and tumor grade.

​

High grade metastatic cancers create high levels of TK1, especially lymphoma.

Cancer Mechanism Diagram with logo.png

Inflammation

Cancer is an inflammatory disease.

​

Inflammation initiates and propagates tumor proliferation and metastasis.

​

Acute phase proteins such as CRP and Haptoglobin are elevated in cancer.

Blood Test

A Novel Blood Test

New Multi-Biomarker Blood Panel for Cancer Activity.

The power of multi-biomarker panels is well proven.

​

Independent metrics of a disease, when combined, help to improve sensitivity and specificity.

​

Combining the power of three unique features of cancer activity, allows for a powerful diagnostic panel AND new metrics for therapeutic monitoring.

Multibiomarker Panel Venn.png
Project 29 alpha bkgnd.png

Current Investigators

Kim Selting

DVM, MS, DACVIM (oncology)

​

Associate Professor

Veterinary Clinical Medicine

University of Illinois

​

Kendra Pope

DVM, DACVIM (oncology), CVA, CVCH, CVFT, CVTP

​

Prism Integrative Veterinary Health

Projects of

Interest

  • Validation in a wide range of tumor types

​

  • Biomarker-driven drug selection

​

  • Monitor disease remission & recurrence

​

  • Applications for early detection/intervention with diet & lifestyle changes

bottom of page